Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer

Phase 2

Completed

• Conditions: Non-small Cell Lung Cancer

• Registration Number: NCT00687817
• Lead Sponsor: Peregrine Pharmaceuticals

Brief Summary

The primary objective of this study is to determine the overall response rate (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally advanced or metastatic non-small cell lung cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-05-28
• Study First Submitted QC: 2008-05-30
• Study Start: 2008-06
• Study First Posted: 2008-06-02
• Primary Completion: 2010-07
• Study Completion: 2010-07
• Status Verified: 2011-03
• Last Update Submitted: 2011-03-23
• Last Update Posted: 2011-03-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

• Adults over age 18 years of age with a life expectancy of at least 3 months
• Histologically or cytologically confirmed non-small cell lung cancer at stage IIIB (with pleural effusion), stage IV, or recurrence
• Measurable disease on cross sectional imaging at least 2 cm in longest diameter (1 cm if measured by spiral CT)
• Adequate hematologic (ANC ≥ 1500 cells/µL; Hemoglobin ≥9 g/dL; platelets ≥100,000/µL and ≤500,000/µL ), renal (serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min), and hepatic function (bilirubin ≤ 1.5 x ULN, ALT ≤ 3 x ULN, AST ≤ 3 x ULN)
• D-dimer ≤ 2 x ULN

Key

Exclusion Criteria

• Small cell or mixed histology
• Known history of bleeding diathesis or coagulopathy
• Any current evidence of clinically significant bleeding defined as gross hematuria, hemoptysis, or GI bleeding
• Any history of thromboembolic events (e.g., deep vein thrombosis or pulmonary thromboembolism)
• Prior chemotherapy, immunotherapy or radiotherapy to an area of measurable disease unless disease had recurred after radiotherapy
• Radiotherapy within 2 weeks preceding Study Day 1
• Symptomatic or clinically active CNS disease or metastatic lesions
• Major surgery within 4 weeks of Study Day 1
• Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)
• Any history of angina pectoris, coronary artery disease or cerebrovascular accident, or transient ischemic attack
• A history of any condition requiring anti-platelet therapy with the exception of general cardiovascular prophylaxis with aspirin. Anti-platelet agents are prohibited during the study.
• Requirement for chronic daily treatment with NSAIDs, anti-platelet drugs, or steroids

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Overall response (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally advanced or metastatic non-small-cell lung cancer	one year

Secondary Outcome Measures

Name	Time	Method
Time to tumor progression, duration of response, overall survival and safety	Approximately 1 year

Trial Locations

Locations (9)

Yashoda Hospital; 🇮🇳 Somajiguda, Hyderabad, India

Apollo Hospital; 🇮🇳 Bannerghatta Rd., Banglore, India

Kidwai Hospital; 🇮🇳 Munigowda Road, Banglore, India

M S Ramaiah Hospital; 🇮🇳 New BEL Rd, Banglore, India

RCC Medical College; 🇮🇳 Trivandrum, Kerala, India

Orchid Nursing Home; 🇮🇳 Phoolanbhaghan, Kolkata, India

Bangalore Institute of Oncology Speciality Centre; 🇮🇳 Sampangi Ram Nagar, Banglore, India

Nizam's Institute of Medical Sciences; 🇮🇳 Panjagutta, Hyderabad, India

Ruby Hall Clinic; 🇮🇳 Pune, India